Related Experiment Videos
[Determination of the stable mitochondrial factor in vivo]
S M Nadtochiĭ1, A Iu Bohuslavs'kyĭ, V F Sahach
1A.A. Bogomoletz Institute of Physiology, National Academy of Sciences of Ukraine, Kiev.
Abstract:
We have determined a release of a stable mitochondrial factor (SMF) into the outflowing blood in vivo. That effect was induced by ischemia/reperfusion or phenylarsin oxide (PAO)--the activators of the mitochondrial permeability transition pore (MPTP) and the oxidative stress. The SMF was measured by a spectrophotometer in the range of wave-lengths 230-260 nm with the absorption maximum of 240-250 nm. The SMF release was accompanied with a decrease in the myocardial contractility, disturbances in cardiodynamics and regional blood circulation. The data obtained have demonstrated that the SMF can be used as a marker of MPTP opening in vivo.
Insights
Researchers identified a stable mitochondrial factor (SMF) released into blood during heart stress. This SMF can serve as a novel biomarker for mitochondrial permeability transition pore (MPTP) opening in living organisms.
Area of Science:
- Cardiovascular Biology
- Mitochondrial Medicine
- Biomarker Discovery
Background:
- Mitochondrial permeability transition pore (MPTP) opening is implicated in various cardiovascular pathologies.
- Ischemia/reperfusion and oxidative stress are known activators of MPTP.
- Identifying reliable in vivo markers for MPTP opening is crucial for understanding and treating cardiac dysfunction.
Purpose of the Study:
- To determine if a stable mitochondrial factor (SMF) is released into the bloodstream.
- To investigate the correlation between SMF release and MPTP activation.
- To evaluate SMF as a potential biomarker for MPTP opening in vivo.
Main Methods:
- Induction of MPTP activation using ischemia/reperfusion or phenylarsin oxide (PAO) in vivo.
- Quantification of SMF in outflowing blood using spectrophotometry (230-260 nm, max absorption 240-250 nm).
- Assessment of myocardial contractility, cardiodynamics, and regional blood circulation.
Main Results:
- A significant release of SMF into the blood was observed following MPTP activation.
- SMF release correlated with decreased myocardial contractility and impaired cardiodynamics.
- Spectrophotometric analysis confirmed SMF presence and characteristics in circulation.
Conclusions:
- Stable mitochondrial factor (SMF) is released into the blood during conditions that activate the MPTP.
- SMF release is associated with detrimental cardiovascular effects.
- SMF shows promise as a novel in vivo biomarker for MPTP opening.